. 2021 Feb 4;35(8):2220–2231. doi: 10.1038/s41375-020-01089-x

Table 3.

Summary of prognostic (both treatment groups) or predictive (either treatment groups).

Outcome	Baseline biomarker	Finding
Improved overall survival	Higher neutrophil count	Prognostic
	Higher platelet count	Prognostic
	Lower percentage of CD45⁺ CD3^– CD19⁺ cells	Predictive (blinatumomab)
Increased likelihood of CR/CRh/CRi	Lower percentage of bone marrow blasts	Prognostic
Increased likelihood of CR/CRh/CRi	Higher percentage of CD45⁺ CD3⁺ CD8⁺ T cells in first salvage	Predictive (blinatumomab)
Increased likelihood of MRD response	Higher percentage of CD3⁺ T cell cells	Prognostic
Adverse events of interest	Percentage of bone marrow blasts	None
	Percentage of CD45⁺ CD3⁺ CD8⁺ cells	None
	Percentage of CD3⁺ cells	None

CR complete remission with full hematologic recovery, CRh complete remission with partial hematologic recovery, CRi complete remission with incomplete hematologic recovery, MRD minimal residual disease.